Free tool
FAERS Monitor: Erivedge
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203388 or its brand name (Erivedge, Vismodegib). Reports on generic versions are filed under their own applications.
Reports
8,927
Serious
3,811
43% of reports
Hospitalization
1,151
Death reported
998
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- muscle spasms2,074
- alopecia1,406
- ageusia1,018
- fatigue980
- death757
- dysgeusia748
- weight decreased741
- nausea722
- decreased appetite708
- diarrhoea476
- constipation383
- off label use383
- asthenia295
- arthralgia284
- no adverse event262
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 122 |
| 2013 | 241 |
| 2014 | 292 |
| 2015 | 468 |
| 2016 | 631 |
| 2017 | 1,465 |
| 2018 | 869 |
| 2019 | 773 |
| 2020 | 710 |
| 2021 | 663 |
| 2022 | 741 |
| 2023 | 674 |
| 2024 | 666 |
| 2025 | 385 |
| 2026 | 223 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,232 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ageusiaSignal | 1,018 | 100.2 | 94.4 | 95,917 |
| muscle spasmsSignal | 2,074 | 26.9 | 25.9 | 51,601 |
| dysgeusiaSignal | 748 | 24.0 | 22.4 | 16,322 |
| alopeciaSignal | 1,406 | 17.0 | 16.2 | 21,179 |
| decreased appetiteSignal | 708 | 7.2 | 6.7 | 3,805 |
| weight decreasedSignal | 741 | 6.3 | 5.8 | 3,311 |
| constipationSignal | 383 | 4.1 | 3.8 | 918 |
| no adverse eventSignal | 262 | 3.4 | 3.0 | 447 |
| fatigueSignal | 980 | 3.0 | 2.8 | 1,324 |
| nauseaSignal | 722 | 2.2 | 2.0 | 460 |
| deathSignal | 757 | 2.1 | 1.9 | 436 |
| asthenia | 295 | 1.8 | 1.7 | 116 |
| diarrhoea | 476 | 1.7 | 1.6 | 153 |
| arthralgia | 284 | 1.6 | 1.4 | 66 |
| off label use | 383 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.